Arcus Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Arcus Biosciences, Inc. on October 28, 2019. The report discloses a corporate governance event involving the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial performance data.
Material Changes
The Board of Directors increased its size from seven (7) to eight (8) members. Antoni Ribas, M.D., Ph.D., was appointed to fill a newly created vacancy as a Class I Director.
Compensation and Governance Details
- Role: Non-employee Director (Class I).
- Cash Retainer: $35,000 annually.
- Equity Grant: Option to purchase 50,000 shares of common stock.
- Vesting Schedule: Substantially equal monthly installments over 36 months of continuous service.
- Acceleration: Vesting accelerates in the event of a Change in Control.
Dr. Ribas is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K, and no other arrangements influenced his selection.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 50,000 share option grant.
- Review the Company's Compensation Program for Non-Employee Directors to confirm the definition of "Change in Control."
- Confirm Dr. Ribas's professional background and potential conflicts of interest in the biotechnology sector.
- Check subsequent filings for any changes to the Board composition or compensation structure.